Celltrion, Inc. vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding IPR2023-00620 filed by Celltrion, Inc. on 2023-02-28. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2023-00620
Filing Date
2023-02-28
Accorded Filing Date
2023-02-28
Institution Decision Date
2023-09-01
Last Modified Date
โ
Proceeding Type
IPR
Termination Date
2023-09-01
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Celltrion, Inc.
Represented By
Green, Loraet alPatent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Fishman, Deborahet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 16 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 10,406,226 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,857,231 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,806,398 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021025214 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021025210 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021039377 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021039353 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 66,512,505 P | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2006021731 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,110,546 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,404,638 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,710,004 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,921,316 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,416,167 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,511,140 B2 | US Continuation / Sibling | View Official Patent → |
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.